Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News| Hematopoiesis News 9.43 October 29, 2018 | |
 | |
| |
TOP STORYDual Cholinergic Signals Regulate Daily Migration of Hematopoietic Stem Cells and Leukocytes At night, central parasympathetic cholinergic signals dampened sympathetic noradrenergic tone and decreased bone marrow (BM) egress of hematopoietic stem and progenitor cells (HSPCs) and leukocytes. However, at daytime, de-repressed sympathetic noradrenergic activity caused predominant BM egress of HSPCs and leukocytes via β3-AR. [Blood] Abstract | |
| |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Using in vivo CRISPR-Cas9 disruption of Dnmt3a in Jak2V617F knockin hematopoietic stem and progenitor cells, investigators showed that Dnmt3a loss blocks the accumulation of erythroid elements and causes fibrotic infiltration within the bone marrow and spleen. [Blood] Abstract Allogeneic transplantation (allo-HCT) has led to the cure of HIV in one individual, raising the question of whether transplantation can eradicate the HIV reservoir. To test this, the authors present a model of allo-HCT in SHIV-infected, cART-suppressed nonhuman primates. [Nat Commun] Full Article Early Human Hemogenic Endothelium Generates Primitive and Definitive Hematopoiesis In Vitro By tracking the dynamic expression of CD31 and CD235a at the onset of hematopoiesis, investigators identified three populations of hematopoietic progenitors, representing primitive and definitive subsets that all emerge from the earliest specified hemogenic endothelium. [Stem Cell Reports] Full Article | Graphical Abstract Scientists performed a unique kinetics study of hematopoiesis in Fancg−/− mouse embryos, between the early embryonic day 11.5 (E11.5) to E12.5 developmental window and E14.5. They revealed a deep HSC defect with exhaustion of proliferative and self-renewal capacities very early during development, together with severe Fanconi anemia clinical and biological manifestations, which were mitigated at E14.5 due to compensatory mechanisms that help to ensure survival of Fancg−/− embryos. [Stem Cell Reports] Full Article Investigators utilized cellular “barcoding” to investigate the impact of different vector designs on the clonal behavior of HSPC during in vivo expansion as a quantitative surrogate assay for genotoxicity in a non-human primate model with high relevance for human biology. [Mol Ther Methods Clin Dev] Abstract | Full Article Researchers found that Cdh1 is highly expressed in human CD34+ hematopoietic stem and progenitor cells (HSPCs) and downregulated in differentiated subsets; whereas, loss of Cdh1 restricts myeloid differentiation, supports B cell development and preserves immature short-term HSPCs without affecting proliferation or viability. [Cell Mol Life Sci] Abstract By using a modified version of Cas9 with reduced nuclease activity in G1 phase of cell cycle when homology‐directed repair (HDR) cannot occur, and transiently increasing the proportion of cells in HDR‐preferred phases, scientists achieved a four‐fold improvement in HDR/non‐homologous end joining ratio over the control condition in vitro, and a significant improvement after xenotransplantation of edited human HSCs into immune‐deficient mice. [Stem Cells] Abstract Researchers showed that NT-embryonic stem cells (NT-ESCs) and induced pluripotent stem cells (iPSCs) derived from the same donors generally displayed similar in vitro commitment capacity toward three germ layer lineages as well as proliferative activity and clonogenic capacity. However, the maturation capacity of NT-ESC-derived hematopoietic progenitors was significantly greater than the corresponding capacity of isogenic iPSC-derived progenitors. [Cell Death Dis] Full Article The authors investigated whether in vitro mechanopriming of human mesenchymal stromal cells could be administered to predictively and significantly improve in vivo hematopoietic recovery after irradiation injury. [Stem Cell Res Ther] Full Article | Press Release Investigators showed that systemically delivered blood platelets decorated with anti-PD-1 antibodies and conjugated to HSCs suppress the growth and recurrence of leukemia in mice. [Nat Biomed Eng] Abstract | Press Release CLINICAL RESEARCHResearchers compared the outcomes of acute myeloid leukemia patients with active disease who received allogeneic stem cell transplantation from a haploidentical donor with post-transplant cyclophosphamide versus an unrelated donor 10/10 and versus unrelated donor 9/10 between 2007 and 2014 and reported to the EBMT registry. [Haematologica] Abstract | Full Article Scientists examined the association of donor cell subsets with outcomes in recipients of myeloablative allogeneic hematopoietic cell transplantation using bone marrow grafts from 2002 to 2014 with related or unrelated donors. [Bone Marrow Transplant] Abstract Subscribe to one of our other 19 science newsletters such as Cord Blood News & Cell Therapy News. | |
| |
| |
REVIEWSThe authors describe the use of ex vivo T cell-depleted grafts as a model for the targeted graft and review evolving knowledge and approaches for further refinement of allografts to improve patient outcomes. [Annu Rev Med] Abstract Emerging Role of Non-Canonical Polycomb Repressive Complexes in Normal and Malignant Hematopoiesis In contrast to canonical polycomb repressive complex (PRC) 1 that is recruited to its target sites in a manner dependent on H3K27me3, non-canonical PRC1 complexes are recruited to their target sites independently of H3K27me3. Among them, PRC1.1, consisting of PCGF1, RING1A/B, KDM2B, and BCOR or BCLRL1, regulates diverse biological processes, including pluripotency, reprogramming, and hematopoiesis. [Exp Hematol] Abstract Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
SCIENCE NEWSOpsona Therapeutics Ltd. to Present Results on Tomaralimab Study Opsona Therapeutics Ltd. announced that it will give an oral presentation on results from its ongoing prospective, open label Phase I/II study being conducted with tomaralimab, its novel proprietary humanized IgG4 monoclonal antibody against toll-like receptor 2, in second and third-line lower risk myelodysplastic syndrome. [Press release from Opsona Therapeutics Ltd. discussing research to be presented at the 60th Annual Meeting of the American Society of Hematology (ASH), San Diego] Press Release | |
| |
INDUSTRY NEWSCelgene Corporation announced results from an open-label Phase II/III National Clinical Trials Network study led by the ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute, part of the National Institutes of Health. [Celgene Corporation] Press Release Genmab A/S announced topline results from the Phase III MAIA study of daratumumab in combination with lenalidomide and dexamethasone versus Rd alone as treatment for newly diagnosed patients who are not candidates for high dose chemotherapy and autologous stem cell transplant. [Genmab A/S] Press Release Omeros Corporation announced that OMS721 has received orphan drug designation from the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. [Omeros Corporation] Press Release Bayer Inc. Receives Approval for Hemophilia A Treatment Jivi® Bayer Inc. announced that Health Canada has approved Jivi® for routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes in previously treated adults and adolescents 12 years of age or older. [Bayer Inc.] Press Release Former Patient Donates $10 Million to Further Blood Cancer Research at UNC Lineberger A former patient of the North Carolina Cancer Hospital and a two-time alumnus of the University of North Carolina at Chapel Hill is showing his gratitude to the center that helped him heal. A $10 million gift will create a new fund supporting ground-breaking research in blood cancer at UNC Lineberger Comprehensive Cancer Center, including lymphoma, leukemia and myeloma research. [University of North Carolina at Chapel Hill] Press Release | |
| |
POLICY NEWS‘Tropical Trump’ Victory in Brazil Stuns Scientists Former military officer Jair Bolsonaro rode a wave of anti-establishment anger to victory in Brazil’s presidential election, leaving many researchers stunned and worried about the future of their country. [Nature News] Editorial Australian Academics Fear Political Interference following Vetoed Projects Australian universities and researchers have condemned the actions of a government minister who vetoed projects that had been selected for funding by expert panels. Academics say that the government’s interference has undermined the integrity of the peer-review system and could damage the country’s reputation as a desirable place to do research. [Nature News] Editorial US Government Halts Heart Stem-Cell Study The US National Heart, Lung, and Blood Institute has paused a clinical trial using stem cells to treat heart failure after questions were raised about the validity of the science behind it. [Nature News] Editorial Top Genomics Institute Clears Director of Bullying and Gender Discrimination The Wellcome Sanger Institute dismissed allegations of harassment and misuse of funds, following an independent investigation. [Nature News] Editorial US Proposal for Defining Gender Has No Basis in Science According to a draft memo leaked to The New York Times, the US Department of Health and Human Services proposes to establish a legal definition of whether someone is male or female based solely and immutably on the genitals they are born with. The move would make it easier for institutions receiving federal funds, such as universities and health programs, to discriminate against people on the basis of their gender identity. [Nature News] Editorial
| |
EVENTSNEW Tumor Immunology and Immunotherapy Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Scientist – Hematology (University Medical Center Freiburg) NEW Research Scientist – Hematological Malignancies (MD Anderson Cancer Center) NEW Postdoctoral Position – Gene Modification in HSCs (University of Wisconsin-Madison) NEW Research Fellow – Stem Cell Biology & Engineering (New York Blood Center) Faculty Positions – Hematology and Oncology (UC Davis) Postdoctoral Position or PhD Student – Bioinformatics in Leukemia (RWTH Aachen Medical School) Postdoctoral Associate – Hematopoiesis and Leukemia (The Jackson Laboratory) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
